Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05158296 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
A Phase 2 study, sponsored by Laboratoires Thea.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT05158296 is a Phase 2 study that was terminated before completion, run by Laboratoires Thea. The registered enrollment target is 7 participants.
The verdict
NCT05158296, a Phase 2 study, was terminated before completion, sponsored by Laboratoires Thea.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
Interventions
- OTHER Sham-procedure
- DRUG Ultevursen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-12-08 |
| Est. Completion | 2022-10-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05158296
The ClinicalTrials.gov registry entry for NCT05158296 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Laboratoires Thea, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham-procedure is the first listed.
NCT05158296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05158296 about?
NCT05158296 is a clinical study titled "Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)". The purpose of this study is to evaluate the efficacy safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
What is the current status of trial NCT05158296?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2021-12-08. Estimated completion is 2022-10-12.
What interventions are being tested in trial NCT05158296?
The interventions under investigation include: Sham-procedure (OTHER), Ultevursen (DRUG).
Who is sponsoring clinical trial NCT05158296?
This trial is sponsored by Laboratoires Thea, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.